These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16354199)

  • 1. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients.
    Bouaziz JD; Ortonne N; Giustiniani J; Schiavon V; Huet D; Bagot M; Bensussan A
    J Invest Dermatol; 2005 Dec; 125(6):1273-8. PubMed ID: 16354199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
    Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
    J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NKG2D ligands expression and NKG2D-mediated NK activity in Sezary patients.
    Dulphy N; Berrou J; Campillo JA; Bagot M; Bensussan A; Toubert A
    J Invest Dermatol; 2009 Feb; 129(2):359-64. PubMed ID: 18754036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and gamma/delta TCR+ T lymphocytes. II. Modulation of natural killer cytotoxicity by anti-Kp43 monoclonal antibody.
    Aramburu J; Balboa MA; Izquierdo M; López-Botet M
    J Immunol; 1991 Jul; 147(2):714-21. PubMed ID: 1830071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
    Yoo EK; Cassin M; Lessin SR; Rook AH
    J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome.
    Poszepczynska-Guigné E; Schiavon V; D'Incan M; Echchakir H; Musette P; Ortonne N; Boumsell L; Moretta A; Bensussan A; Bagot M
    J Invest Dermatol; 2004 Mar; 122(3):820-3. PubMed ID: 15086570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer.
    Mizutani Y; Okada Y; Yoshida O; Bonavida B
    Cancer Biother Radiopharm; 1996 Dec; 11(6):385-91. PubMed ID: 10851499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.
    Bensussan A; Remtoula N; Sivori S; Bagot M; Moretta A; Marie-Cardine A
    J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides.
    Haynes BF; Bunn P; Mann D; Thomas C; Eisenbarth GS; Minna J; Fauci AS
    J Clin Invest; 1981 Feb; 67(2):523-30. PubMed ID: 6970206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity.
    Seo N; Tokura Y; Matsumoto K; Furukawa F; Takigawa M
    Clin Exp Immunol; 1998 Jun; 112(3):403-9. PubMed ID: 9649208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization and utilization of a monoclonal antibody inhibiting porcine natural killer cell activity for isolation of natural killer and killer cells.
    Dato ME; Kim YB
    J Immunol; 1990 Jun; 144(11):4452-62. PubMed ID: 1971298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sézary syndrome by flow cytometry.
    Bahler DW; Hartung L; Hill S; Bowen GM; Vonderheid EC
    Cytometry B Clin Cytom; 2008 May; 74(3):156-62. PubMed ID: 18061949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of VEP13 monoclonal antibody for definition of natural killer cells: spontaneous killer cells directed against fresh human leukaemia cells carry the VEP13 antigen.
    Ziegler-Heitbrock HW; Fütterer A; Rumpold H; Kraft D; Munker R; Riethmüller G
    Clin Exp Immunol; 1984 Nov; 58(2):470-7. PubMed ID: 6333947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.
    Nikolova M; Musette P; Bagot M; Boumsell L; Bensussan A
    Blood; 2002 Aug; 100(3):1019-25. PubMed ID: 12130517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of circulating T-cell clones in Sezary syndrome.
    Ortonne N; Huet D; Gaudez C; Marie-Cardine A; Schiavon V; Bagot M; Musette P; Bensussan A
    Blood; 2006 May; 107(10):4030-8. PubMed ID: 16418328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment.
    Hotta R; Ohira M; Matsuura T; Muraoka I; Tryphonopoulos P; Fan J; Tekin A; Selvaggi G; Levi D; Ruiz P; Ricordi C; Vianna R; Ohdan H; Waldmann H; Tzakis AG; Nishida S
    PLoS One; 2016; 11(8):e0161618. PubMed ID: 27560943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.